NEXT-GENERATION
IMMUNOTHERAPEUTICS

AGAINST SARS-CoV-2

map_blue_edited.jpg

DiosCURE is advancing next-generation, best-in-class immunotherapeutics to prevent and treat SARS-CoV-2 infections.

DiosCURE_ (41).jpeg
DiosCURE_ (19).jpeg
Render_ACE2_Linker.png

Our lead drug candidates DIOS-202 and DIOS-203 are single-chain antibodies that uniquely bind to different surface structures of the viral spike protein.

 

This approach allows to develop novel immunotherapies that are highly efficacious, well-tolerated and suppress mutational escape by the virus. In addition, our antibodies are amenable to a broad range of clinical applications and can be produced by a cost-efficient manufacturing process.

DiosCURE_ (15).jpeg
 

Next-generation 

immunotherapies against SARS-CoV-2

People-powered
Expertise